Locations
Company type
Result types
Industries
Employees
Founding year
The B2B platform for the best purchasing descision. Identify and compare relevant B2B manufacturers, suppliers and retailers
Close
Filter
Result configuration
Continents
Select continent
Locations
Result types
Company type
Select company type
Industries
Select industry
Company status
Select company status preset
Number of employees
Min.
Max.
Founding year
T Cell Nouveau
Tokyo, Japan
A
1-10 Employees
2021
Key takeaway
T Cell Nouveau Inc. is advancing CAR-T cell therapy through its innovative Hybrid CAR T-cell approach, which they believe is a significant advancement in the fight against solid tumors, surpassing traditional CAR and TCR-T cell therapies. Their commitment to research and development in cancer immunotherapeutics positions them at the forefront of this transformative technology.
Reference
Product
Technology | T Cell Nouveau Inc.
CAR-T細胞治療 自己由来CAR-T細胞治療
ThinkCyte
Tokyo, Japan
A
11-50 Employees
2016
Key takeaway
The company is advancing cell therapy through its innovative Ghost Cytometry technology, which enables label-free characterization and isolation of cells at high throughput. This approach enhances the identification of various cell types, including T cells, which are crucial for CAR-T cell therapy.
Reference
Product
Cell Therapy - ThinkCyte
Label-free Monitoring and Isolation of Target Cells Our Solution for Cell Therapy Conventionally, surface markers or stains have been necessary to characterize and isolate target cells in the cell therapy manufacturing process. By applying Ghost Cytometry, we perform label-free characterization and isolation of cells at high throughput by using machine predicted “in-silico” labels. Our technology can classify and isolate cells based on morphological differences and has been used for identifying live and dead cells, activated and resting T cells, and differentiated and undifferentiated stem cells. It has also been used to assess more subtle morphological variations in cells and organelles including cell-cycle phases, glycolytic levels, and apoptotic status. This technology … Continued
Thyas Co. Ltd.
Kyoto, Japan
A
1-10 Employees
2015
Key takeaway
The company, サイアス株式会社, specializes in regenerating T cells from human iPS cells, focusing on developing regenerative immunotherapy products for cancer and infections. Their research, led by globally recognized experts in T cell differentiation from iPS cells, is directly relevant to advancements in CAR-T cell therapy.
Reference
Core business
サイアス株式会社
サイアス株式会社はヒトiPS細胞からT細胞を再生し、がんや感染症に対する再生免疫細胞療法の製剤を提供することを事業目的としています。
Looking for more accurate results?
Find the right companies for free by entering your custom query!
25M+ companies
250M+ products
Free to use
AceRNA
Kyoto, Japan
A
1-10 Employees
2018
Key takeaway
The company is a biotech startup dedicated to creating innovative genetic therapies that specifically target disease-causing cells, which aligns with the principles of CAR-T cell therapy. They aim to develop transformative treatments through partnerships and advanced technologies like RNA Switches.
Reference
Core business
News - aceRNA
aceRNA
Minaris Regenerative Medicine
Tokyo, Japan
A
501-1000 Employees
-
Key takeaway
Minaris Regenerative Medicine is a prominent CDMO specializing in the production of cell and gene therapy products, including CAR-T cell therapy. With over 20 years of experience and state-of-the-art facilities across multiple regions, the company ensures high-quality manufacturing and development solutions for life-changing therapies.
Reference
Service
Chargenzertifizierung | Minaris Regenerative Medicine
For cell and gene therapy products manufactured outside the European Union, Minaris Regenerative Medicine offers batch release to the EU market by Qualified Persons (QP).
VC Cell Therapy
Kyōtango, Japan
A
- Employees
2021
Key takeaway
The company is focused on developing processes to consistently generate high-quality cells for clinical use, which is essential for therapies like CAR-T cell therapy. Additionally, they are considering logistics for providing ready-to-use formulations, indicating a commitment to advancing cell therapy solutions.
Reference
Core business
株式会社VC Cell Therapy
NEWS
AccuRna
Tokyo, Japan
A
1-10 Employees
2015
Key takeaway
AccuRna is focused on advancing drug delivery systems for nucleic acid therapeutics, which may have implications for innovative cancer treatments like CAR-T cell therapy. Their commitment to developing effective therapies for refractory diseases aligns with the broader goal of enhancing treatment options through novel delivery methods.
Reference
Product
Therapeutic Vaccine – AccuRna, Inc.
Chordia Therapeutics
Fujisawa, Japan
A
11-50 Employees
2017
Key takeaway
Chordia Therapeutics is dedicated to delivering first-in-class cancer drugs to patients, highlighting their focus on innovative therapies. Their R&D-oriented approach positions them well in the pharmaceutical landscape, which may relate to advancements in treatments like CAR-T cell therapy.
Reference
Core business
Company - Chordia Therapeutics
Mission We are passionate to deliver first in class can
ReproCELL
Yokohama, Japan
A
51-100 Employees
2003
Key takeaway
REPROCELL offers a comprehensive range of services and products that support translational research, including expertise in stem cell research and the supply of induced pluripotent stem cells (iPSCs) for clinical applications. The company's focus on developing novel regenerative medicine therapies, particularly for neurodegenerative diseases, highlights its commitment to advancing innovative treatments.
Reference
Core business
REPROCELL Global
Want to better translate your discoveries into therapies? Speak to our human tissue and stem cell experts about your research challenges.
MiCAN Technologies
Kyoto, Japan
A
1-10 Employees
2016
Key takeaway
MiCAN Technologies, Inc. specializes in producing high precision human blood cells using regenerative medicine technologies, which can significantly enhance the evaluation of drug efficacy and safety. Their innovative approach, particularly with the development of cMylc cells for COVID-19 research, underscores their commitment to advancing therapeutic evaluations.
Reference
Core business
MiCAN Technologies / マイキャン・テクノロジーズ株式会社
For research on malaria,our newly developed MPV cells will solve the shortage of supply of reticulocyte cells and support researches to eradicate such diseases.
Technologies which have been searched by others and may be interesting for you:
When exploring the CAR-T cell therapy industry in Japan, several key considerations come into play. The regulatory landscape is crucial, as Japan has specific guidelines and approval processes for advanced therapies, including CAR-T. The Pharmaceuticals and Medical Devices Agency (PMDA) oversees the approval of these therapies, ensuring they meet safety and efficacy standards. Additionally, understanding the challenges of high production costs and complex manufacturing processes can impact the viability of companies in this sector. Opportunities exist due to Japan's aging population and increasing cancer prevalence, driving demand for innovative therapies. The competitive landscape is dynamic, with both domestic and international players vying for market share, necessitating a thorough analysis of emerging companies and established firms. Global collaborations and partnerships are also essential, as many Japanese companies engage in research and development with international firms, enhancing their technological capabilities. Furthermore, environmental considerations are becoming increasingly important, particularly in terms of sustainable manufacturing practices and waste management in the production of cell therapies. Overall, a comprehensive understanding of the regulatory environment, market needs, competitive dynamics, and potential environmental impacts will provide valuable insights for anyone interested in the CAR-T cell therapy industry in Japan.
Some interesting numbers and facts about your company results for CAR-T Cell Therapy
| Country with most fitting companies | Japan |
| Amount of fitting manufacturers | 38 |
| Amount of suitable service providers | 24 |
| Average amount of employees | 11-50 |
| Oldest suiting company | 2003 |
| Youngest suiting company | 2021 |
Some interesting questions that has been asked about the results you have just received for CAR-T Cell Therapy
What are related technologies to CAR-T Cell Therapy?
Based on our calculations related technologies to CAR-T Cell Therapy are Biomedical (Red), Bioinformatics (Gold), Environmental Biotechnology (Grey), Agricultural Biotechnology (Green), Food Related Biotechnology (Yellow)
Who are Start-Ups in the field of CAR-T Cell Therapy?
Start-Ups who are working in CAR-T Cell Therapy are T Cell Nouveau
Which industries are mostly working on CAR-T Cell Therapy?
The most represented industries which are working in CAR-T Cell Therapy are Other, Biotechnology, IT, Software and Services, Medical, Pharmaceuticals
How does ensun find these CAR-T Cell Therapy Companies?
ensun uses an advanced search and ranking system capable of sifting through millions of companies and hundreds of millions of products and services to identify suitable matches. This is achieved by leveraging cutting-edge technologies, including Artificial Intelligence.